Castlekeep Investment Advisors LLC Takes $37.49 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Castlekeep Investment Advisors LLC purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,796,552 shares of the biopharmaceutical company's stock, valued at approximately $37,494,000. Castlekeep Investment Advisors LLC owned about 1.51% of Catalyst Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of CPRX. Barclays PLC raised its stake in shares of Catalyst Pharmaceuticals by 129.4% during the 3rd quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company's stock valued at $4,939,000 after purchasing an additional 140,129 shares during the period. Franklin Resources Inc. lifted its stake in Catalyst Pharmaceuticals by 3.4% in the third quarter. Franklin Resources Inc. now owns 59,164 shares of the biopharmaceutical company's stock worth $1,221,000 after purchasing an additional 1,967 shares during the last quarter. JPMorgan Chase & Co. grew its position in Catalyst Pharmaceuticals by 9.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company's stock worth $8,116,000 after acquiring an additional 33,888 shares during the last quarter. CWA Asset Management Group LLC raised its holdings in Catalyst Pharmaceuticals by 25.5% during the 4th quarter. CWA Asset Management Group LLC now owns 33,698 shares of the biopharmaceutical company's stock valued at $703,000 after buying an additional 6,853 shares during the last quarter. Finally, Oliver Luxxe Assets LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 103.5% during the fourth quarter. Oliver Luxxe Assets LLC now owns 69,250 shares of the biopharmaceutical company's stock worth $1,445,000 after purchasing an additional 35,225 shares during the period. Hedge funds and other institutional investors own 79.22% of the company's stock.

Analyst Upgrades and Downgrades

CPRX has been the topic of several research reports. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Stephens reissued an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Robert W. Baird increased their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, March 3rd. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Finally, Bank of America reissued a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $32.29.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 62,975 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gary Ingenito sold 44,904 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their position. The disclosure for this sale can be found here. 10.40% of the stock is currently owned by corporate insiders.

Catalyst Pharmaceuticals Price Performance

NASDAQ CPRX traded up $0.40 during mid-day trading on Wednesday, hitting $23.46. The stock had a trading volume of 1,341,346 shares, compared to its average volume of 1,105,936. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.47 and a twelve month high of $26.16. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of 19.88, a PEG ratio of 3.31 and a beta of 0.70. The firm's 50 day moving average is $22.96 and its 200 day moving average is $22.36.

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.53 by $0.10. Catalyst Pharmaceuticals had a net margin of 31.01% and a return on equity of 40.79%. As a group, equities research analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.9 earnings per share for the current year.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.